Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-01-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-2084PMID 20068087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC).

  2016cited by this paper
• Correction: Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

  2010cited by this paper
• Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.

  2009cited by this paper
• Molecular profiling to predict hepatocellular carcinoma outcome

  2009cited by this paper
• A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

  2009cited by this paper
• Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

  2009cited by this paper
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• The insulin‐like growth factor system and sarcomas

  2009cited by this paper
• Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC).

  2009influential reference
• Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

  2009cited by this paper
• Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

  2009cited by this paper
• Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.

  2009cited by this paper
• A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

  2009cited by this paper
• Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

  2009cited by this paper
• Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo.

  2009cited by this paper
• mTOR inhibitors for hepatocellular cancer: a forward-moving target

  2009cited by this paper
• Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

  2009cited by this paper
• A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): An interim safety report.

  2009cited by this paper
• Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma

  2009cited by this paper
• Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab

  2009cited by this paper
• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  2009cited by this paper
• Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

  2008cited by this paper
• Pivotal role of mTOR signaling in hepatocellular carcinoma.

  2008cited by this paper
• Design and endpoints of clinical trials in hepatocellular carcinoma.

  2008cited by this paper
• An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.

  2008cited by this paper
• Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models

  2008cited by this paper
• Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

  2008cited by this paper
• Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

  2008cited by this paper
• Modes of resistance to anti-angiogenic therapy

  2008cited by this paper
• Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.

  2008cited by this paper
• Drug development of MET inhibitors: targeting oncogene addiction and expedience

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

  2008cited by this paper
• Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps

  2008cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial

  2008cited by this paper
• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial

  2008cited by this paper
• Sirolimus‐based immunosuppression following liver transplantation for hepatocellular carcinoma

  2008cited by this paper
• Systemic therapy of hepatocellular carcinoma: Are we making progress?

  2008cited by this paper
• Reference

  2008cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation

  2007cited by this paper
• Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)

  2007cited by this paper
• High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies

  2007cited by this paper
• Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma

  2007cited by this paper
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• Angiogenesis Soluble Factors as Hepatocellular Carcinoma Noninvasive Markers for Monitoring Hepatitis C Virus Cirrhotic Patients Awaiting Liver Transplantation

  2007cited by this paper
• Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  2007cited by this paper
• A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

  2007cited by this paper
• Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.

  2006cited by this paper
• Hepatocellular carcinoma pathogenesis: from genes to environment

  2006cited by this paper
• Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.

  2006cited by this paper
• Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

  2006cited by this paper
• Phase II study of erlotinib in patients with advanced biliary cancer.

  2006cited by this paper
• Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

  2006cited by this paper
• Suppression of Tumor Growth Using Antisense Oligonucleotide Against Survivin in an Orthotopic Transplant Model of Human Hepatocellular Carcinoma in Nude Mice

  2006cited by this paper
• A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells

  2006cited by this paper
• Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis.

  2006cited by this paper
• Hepatocellular carcinoma: the need for progress.

  2005cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease

  2005cited by this paper
• A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma.

  2005cited by this paper
• Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.

  2005cited by this paper
• Altered expression of vascular endothelial growth factor, fibroblast growth factor‐2 and endostatin in patients with hepatocellular carcinoma

  2005cited by this paper
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

  2005cited by this paper
• A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization

  2005influential reference
• Management of hepatocellular carcinoma

  2005cited by this paper
• Pathogenesis of hepatocellular carcinoma.

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study.

  2004cited by this paper
• mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms

  2004cited by this paper
• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

  2003cited by this paper
• Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.

  2003cited by this paper
• Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.

  2002cited by this paper
• Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma

  2002cited by this paper
• Expression of Survivin Messenger RNA Correlates With Poor Prognosis in Patients With Hepatocellular Carcinoma

  2002cited by this paper
• The IGF axis and hepatocarcinogenesis

  2001cited by this paper
• Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma.

  2001cited by this paper
• The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma.

  2001cited by this paper
• Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

  2001cited by this paper
• Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.

  2001cited by this paper
• Survivin promotes cell proliferation in human hepatocellular carcinoma

  2000cited by this paper
• Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma.

  1997cited by this paper
• Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor

  1996cited by this paper
• Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines

  1996cited by this paper
• Management of hepatocellular carcinoma.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• Hepatocellular carcinoma.

  1986cited by this paper
• Clinical Cancer Research

  1941cited by this paper

• Tumor-specific glyco-detonators: A neuraminidase-3-gated programmable DNA Nanoarchitectonics for liver cancer-exclusive chemotherapy.

  2025cites this paper
• Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions

  2025cites this paper
• Clinical application of radioiodinated antibodies: where are we?

  2022cites this paper
• GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells

  2021cites this paper
• HBP1-mediated transcriptional repression of AFP inhibits hepatoma progression

  2021cites this paper
• Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma

  2021cites this paper
• Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation

  2020cites this paper
• Transcription co-activator P300 activates Elk1-aPKC-ι signaling mediated epithelial-to-mesenchymal transition and malignancy in hepatocellular carcinoma

  2020cites this paper
• DDDT_A_243383 1609..1620

  2020influential citation
• HBP1-mediated transcriptional regulation of AFP and its impact on hepatoma

  2020cites this paper
• Novel molecular targets in hepatocellular carcinoma

  2020cites this paper
• Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.

  2020cites this paper
• Amination of Graphene Oxide Leads to Increased Cytotoxicity in Hepatocellular Carcinoma Cells

  2020cites this paper
• Therapeutic potential of functionalized siRNA nanoparticles on regression of liver cancer in experimental mice

  2019cites this paper
• Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy

  2019cites this paper
• Protopanaxadiol inhibits epithelial–mesenchymal transition of hepatocellular carcinoma by targeting STAT3 pathway

  2019cites this paper
• Anti-cancer effects of ethanol extract of Reynoutria japonica Houtt. radix in human hepatocellular carcinoma cells via inhibition of MAPK and PI3K/Akt signaling pathways.

  2019cites this paper
• S-Adenosylmethionine Affects Cell Cycle Pathways and Suppresses Proliferation in Liver Cells

  2019cites this paper
• A miR‐194/PTBP1/CCND3 axis regulates tumor growth in human hepatocellular carcinoma

  2019cites this paper
• Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt

  2018cites this paper
• Ophiopogonin Binduceshepatocellular carcinoma MHCC 97-H cell apoptosis and decreases invasion through inhibition of the JAK 2 / STAT 3 signaling pathway

  2018cites this paper
• Innovations in the Management of Hepatocellular Carcinoma

  2018cites this paper
• Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

  2018influential citation
• ARHGAP9 suppresses the migration and invasion of hepatocellular carcinoma cells through up-regulating FOXJ2/E-cadherin

  2018cites this paper
• Coupling function of cyclin‐dependent kinase 2 and Septin2 in the promotion of hepatocellular carcinoma

  2018cites this paper
• High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients

  2018cites this paper
• Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma

  2017cites this paper
• Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN

  2017cites this paper
• Introductory Chapter: Updates on the Management of Hepatocellular Carcinoma

  2017cites this paper
• HepG2 and human healthy hepatocyte in vitro culture and co-culture in PCL electrospun platforms

  2017cites this paper
• Survivin downregulation using siRNA nanoliposomes inhibits cell proliferation and promotes the apoptosis of MHCC-97H hepatic cancer cells: An in vitro and in vivo study

  2017cites this paper
• Design, Synthesis and Biological Screening of Novel Cucsinspired Estrone Analogues Towards Treatment of Hepatocellular Carcinoma

  2017cites this paper
• TRIM 66 knockdown inhibits cell growth , but induces cell cycle arrest and apoptosis of hepatocellular carcinoma cells

  2017cites this paper
• Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics

  2016cites this paper
• Knockdown of Rhotekin 2 expression suppresses proliferation and invasion and induces apoptosis in hepatocellular carcinoma cells.

  2016cites this paper
• Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

  2016cites this paper
• Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.

  2016cites this paper
• MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.

  2016cites this paper
• Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

  2016cites this paper
• Overexpression of PCBP 2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma

  2016cites this paper
• Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma

  2016cites this paper
• Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.

  2016cites this paper
• Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.

  2015cites this paper
• Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators

  2015cites this paper
• Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.

  2015cites this paper
• Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase

  2015cites this paper
• Multi-omics in prognosis of hepatocellular carcinoma.

  2015cites this paper
• Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.

  2015cites this paper
• Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases

  2014cites this paper
• The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy.

  2014cites this paper
• Identification of anticancer drugs for hepatocellular carcinoma through personalized genome‐scale metabolic modeling

  2014cites this paper
• The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma

  2014cites this paper
• Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy

  2014cites this paper
• A preclinical evaluation of a novel multikinase inhibitor, SKLB‐329, as a therapeutic agent against hepatocellular carcinoma

  2014cites this paper
• Fibroblast growth factor signaling in liver carcinogenesis

  2014cites this paper
• Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.

  2014cites this paper
• Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.

  2014cites this paper
• New Oncogenic Drivers in Hepatocellular Carcinoma: Role of the RNA Binding Protein Hu antigen R

  2014cites this paper
• Identification of FKBP11 as a biomarker for hepatocellular carcinoma.

  2013cites this paper
• Development of Tivantinib as Treatment for Hepatocellular Carcinoma

  2013cites this paper
• Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective

  2013cites this paper
• Emerging Targeted Strategies in Advanced Hepatocellular Carcinoma

  2013cites this paper
• Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro

  2013cites this paper
• Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

  2013cites this paper
• Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen

  2013cites this paper
• The new golden era for radioimmunotherapy: not just for lymphomas anymore.

  2013cites this paper
• Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

  2013cites this paper
• MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability

  2013cites this paper
• Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.

  2013cites this paper
• Management of Hepatocellular Carcinoma: Updated Review

  2013cites this paper
• Guttiferone F from the fruit of Garcinia multiflora and its anti-hepatocellular carcinoma activity

  2013cites this paper
• Systemische Therapie des hepatozellulären Karzinoms

  2013cites this paper
• Expression Profiling of Hepatocellular Carcinoma

  2013cites this paper
• The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy.

  2012cites this paper
• Pathways and targets in hepatocellular carcinoma

  2012cites this paper
• Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA

  2012cites this paper
• Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.

  2012cites this paper
• A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

  2012cites this paper
• Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

  2012cites this paper
• Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.

  2012cites this paper
• Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition

  2012cites this paper
• Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma

  2012cites this paper
• Curcumin-Induced Apoptosis in Human Hepatocellular Carcinoma J5 Cells: Critical Role of Ca+2-Dependent Pathway

  2012cites this paper
• Development of human hepatocellular carcinoma cell-targeted protein cages.

  2012cites this paper
• Survivin-mediated Therapeutic Efficacy of Gemcitabine through Glucose-regulated Protein 78 in Hepatocellular Carcinoma

  2012cites this paper
• Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli

  2012cites this paper
• Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report

  2011cites this paper
• Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  2011cites this paper
• Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.

  2011cites this paper
• Drug Interaction between Ginseng Extract (GE) and Sorafenib

  2011cites this paper
• Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled

  2011influential citation
• Author Summary: Abstract and Brief Discussion

  2011cites this paper
• Non‐invasive in vivo imaging for liver tumour progression using an orthotopic hepatocellular carcinoma model in immunocompetent mice

  2011cites this paper
• Novel therapeutic strategies to target RCAS1, which induces apoptosis via ectodomain shedding.

  2011cites this paper
• Targeting metastatic upper gastrointestinal adenocarcinomas.

  2011cites this paper
• Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: involvement of ROS-dependent ER-stress.

  2011cites this paper
• Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC

  2011cites this paper
• Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma

  2011cites this paper
• Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling.

  2011cites this paper
• Surgical approach for extrahepatic metastasis of HCC in the abdominal cavity.

  2011cites this paper